Epidemiology of clinical isolates of Candida albicans and their susceptibility to triazoles (Q44233644)

1 December 2017

title

Epidemiology of clinical isolates of Candida albicans and their susceptibility to triazoles (English)

1 reference

ORCID Public Data File 2021

1 December 2017

1 reference

1 reference

author name string

Wroblewska MM

1

1 reference

1 December 2017

Swoboda-Kopec E

2

1 reference

1 December 2017

Rokosz A

3

1 reference

1 December 2017

Krawczyk E

4

1 reference

1 December 2017

Marchel H

5

1 reference

1 December 2017

Luczak M

6

1 reference

1 December 2017

publication date

1 December 2002

1 reference

International Journal of Antimicrobial Agents

1 December 2017

published in

1 reference

1 December 2017

volume

20

1 reference

1 December 2017

issue

6

1 reference

1 December 2017

page(s)

472-475

1 reference

The epidemiology of hematogenous candidiasis caused by different Candida species

1 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900246-7

7 January 2021

Putative virulence factors of Candida albicans

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900246-7

7 January 2021

Fluconazole penetration into cerebrospinal fluid: implications for treating fungal infections of the central nervous system

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900246-7

7 January 2021

Role of azoles in antifungal therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900246-7

7 January 2021

Comparison of two alternative microdilution procedures with the National Committee for Clinical Laboratory Standards reference macrodilution method M27-P for in vitro testing of fluconazole-resistant and -susceptible isolates of Candida albicans

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900246-7

7 January 2021

Susceptibility testing of Candida species: comparison of NCCLS microdilution method with Fungitest.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900246-7

7 January 2021

Comparative evaluation of Fungitest-, Neo-Sensitabs- and M27T-NCCLS broth microdilution methods for antifungal drug susceptibility testing of Candida species and Cryptococcus neoformans

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900246-7

7 January 2021

Application of CHROMagar Candida for rapid screening of clinical specimens for Candida albicans, Candida tropicalis, Candida krusei, and Candida (Torulopsis) glabrata.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900246-7

7 January 2021

Prevalence and antifungal susceptibility of 442 Candida isolates from blood and other normally sterile sites: results of a 2-year (1996 to 1998) multicenter surveillance study in Quebec, Canada

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900246-7

7 January 2021

Prospective study of Candida species in patients at a comprehensive cancer center

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900246-7

7 January 2021

Resistance of Candida species to fluconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900246-7

7 January 2021

In vitro susceptibility of 137 Candida sp. isolates from HIV positive patients to several antifungal drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900246-7

7 January 2021

Clinical, cellular, and molecular factors that contribute to antifungal drug resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900246-7

7 January 2021

Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900246-7

7 January 2021

National surveillance of nosocomial blood stream infection due to Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900246-7

7 January 2021

A two year global evaluation of the susceptibility of Candida species to fluconazole by disk diffusion

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900246-7

7 January 2021

Does long-term itraconazole prophylaxis result in in vitro azole resistance in mucosal Candida albicans isolates from persons with advanced human immunodeficiency virus infection? The National Institute of Allergy and Infectious Diseases Mycoses stu

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900246-7

7 January 2021

Decrease in Candida albicans strains with reduced susceptibility to fluconazole following changes in prescribing policies

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900246-7

7 January 2021

Itraconazole susceptibilities of fluconazole susceptible and resistant isolates of five Candida species

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2802%2900246-7

7 January 2021

10.1016/S0924-8579(02)00246-7

Identifiers

DOI

1 reference

1 December 2017

1 reference